On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery

Blood Transfusion

Volumn 10, Issue 1, 2012, Pages 8-22

  Muñoz, Manuel ^a   Garciá Erce, José Antonio ^b   Cuenca, Jorge ^c   Bisbe, Elvira ^d   Naveira, Enrique ^e  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL SAN JORGE   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d Department of Anesthesiology   (Spain)

^e Clinica Santa Elena   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRIC CARBOXYMALTOSE; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS GLUCONATE; FERUMOXYTOL; HEMOGLOBIN; HIGH MOLECULAR WEIGHT IRON DEXTRAN; IRON; IRON DERIVATIVE; IRON DEXTRAN; IRON ISOMALTOSIDE 1000; LOW MOLECULAR WEIGHT IRON DEXTRAN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; ANEMIA OF CHRONIC DISEASE; BLOOD AUTOTRANSFUSION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MEGADOSE; ELECTIVE SURGERY; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; MEAN CORPUSCULAR HEMOGLOBIN; ORTHOPEDIC SURGERY; OVERT ANEMIA; POSTOPERATIVE HEMORRHAGE; REVIEW; SURGICAL PATIENT; TRANSFERRIN BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

BLOOD TRANSFUSION; HUMANS; IRON; ORTHOPEDIC PROCEDURES; PREOPERATIVE CARE; PREOPERATIVE PERIOD;

EID: 84855724252     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2011.0061-11     Document Type: Review

References (80)

1. Spahn DR. Anemia and patient blood management in hip and knee surgery. A systematic review of the literature. Anesthesiology 2010; 113: 482-95.
2. Wu WC, Schifftner TL, Henderson WG, et al. Preoperative hematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA 2007; 297: 2481-8. (Pubitemid 46953401)
3. Saleh E, McClelland DBL, Hay A, et al. Prevalence of anaemia before major joint arthroplasty and the potential impact of pre-operative investigation and correction on peri-operative blood transfusions. Br J Anaesth 2007; 99: 801-8. (Pubitemid 351773379)
4. Bisbe E, Castillo J, Sáez M, et al. Prevalence of preoperative anemia and hematinic deficiencies in patients scheduled for major orthopedic surgery. Transfus Altern Transfus Med 2008; 4: 166-73.
5. Salido JA, Marín LA, Gómez LA, et al. Pre-operative haemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg Am 2002; 84-A: 216-20.
6. Aderinto J, Brenkel IJ. Pre-operative predictors of the requirement for blood transfusion following total hip replacement. J Bone Joint Surg Br 2004; 86-B: 970-3. (Pubitemid 39255858)
7. García-Erce JA, Solano VM, Cuenca J, Ortega P. La hemoglobina preoperatoria como único factor predictor de las necesidades transfusionales en la artroplastia de rodilla. Rev Esp Anestesiol Reanim 2002; 49: 254-60.
8. Rosencher N, Kerkkamp HE, Macheras G, et al.; OSTHEO Investigation: Orthopedic Surgery Transfusion Haemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003; 43: 459-69. (Pubitemid 36428328)
9. García-Erce JA, Cuenca J, Solano VM. Factores predictores de transfusión en pacientes mayores de 65 años con fractura subcapital de cadera. Med Clin (Barc) 2003; 120: 161-6. (Pubitemid 36266969)
10. Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology 2009; 110: 574-81.
11. Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: Iron deficiency and iron overload. J Clin Pathol 2011; 64: 287-96.
12. Mercuriali F, Inghilleri G. Proposal of an algorithm to help the choice of the best transfusion strategy. Curr Res Med Opin 1996; 13: 465-78. (Pubitemid 26402690)
13. Beris P, Muñoz M, García-Erce JA, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 2008; 100: 599-604 (Pubitemid 351774360)
14. Goodnough LT, Maniatis A, Earnshaw P, et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines Br J Anaesth 2011; 106: 13-22.
15. Muñoz M, Romero A, Gómez JF, et al. Utility of point-of-care haemoglobin measurement in the HemoCue-B haemoglobin for the initial diagnosis of anaemia. Clin Lab Haematol 2005; 27: 99-104. (Pubitemid 40520502)
16. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747-50. (Pubitemid 43289347)
17. Cook JD. Diagnosis and management of iron-deficiency anaemia. Best Pract Res Clin Haematol 2005; 18: 319-32. (Pubitemid 40298373)
18. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002; 48: 1066-76. (Pubitemid 34680903)
19. Basora C, Deulofeu R, Salazar F, et al. Improved preoperative iron status assessment by soluble transferrin receptor in elderly patients undergoing knee and hip replacement. Clin Lab Haem 2006; 28: 370-5 (Pubitemid 44730200)
20. Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: Molecular basis of iron homeostasis. J Clin Pathol 2011; 64: 281-6.
21. Thomas C, Kobold U, Balan S, Roeddiger R, Thomas L. Serum hepcidin-25 may replace the ferritin index in the Thomas plot in assessing iron status in anemic patients. Int J Lab Hematol 2011; 33: 187-93.
22. Thomas L, Franck S, Messinger M, Linssen J, et al. Reticulocyte hemoglobin measurement-comparison of two methods in the diagnosis of iron-restricted erythropoiesis. Clin Chem Lab Med 2005; 43: 1193-202. (Pubitemid 41600670)
23. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (RetHe) and assessment of iron-deficient states. Clin Lab Haematol 2006; 28: 303-8. (Pubitemid 44453675)
24. Canals C, Remacha AF, Sarda MP, et al. Clinical utility of the new Sysmex XE 2100 parameter - reticulocyte hemoglobin equivalent - in the diagnosis of anemia. Haematologica 2005; 90: 1133-4. (Pubitemid 41323514)
25. Ganzoni AM. Eisen-Dextran intravenös: therapeutische und experimentalle Möglichkeiten. Schweizerische medizinische Wochenschrift 1970; 100: 301-3.
26. Crichton RR, Danielsson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. UNI-Med Verlag AG, Bremen, 2008.
27. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008; 103:1299-307. (Pubitemid 351678000)
28. Andrews CM, Lane DW, Bradley JG. Iron pre-load for major joint replacement. Transfus Med 1997; 7: 281-6. (Pubitemid 28051962)
29. Cuenca J, García-Erce JA, Martínez F, et al. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Inter J Surg 2007; 5: 89-94. (Pubitemid 46590853)
30. Muñoz M, Kühlmorgen B, Ariza D, et al. Which patients are more likely to benefit of postoperative shed blood reinfusion after unilateral total knee replacement? Vox Sang 2007; 92: 136-41. (Pubitemid 46239231)
31. Rogers BA, Cowie A, Alcock C, Rosson JW. Identification and treatment of anaemia in patients awaiting hip replacement. Ann R Coll Surg Engl 2008; 90: 504-7.
32. Weber EW, Slappendel R, Hémon Y, et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: the European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 2005; 22: 249-57. (Pubitemid 40731986)
33. Zauber NP, Zauber AG, Gordon FJ, et al. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992; 267: 525-7.
34. Sutton PM, Cresswell T, Livesey JP, et al. Treatment of anaemia after joint replacement. J Bone Joint Surg Br 2004; 86-B: 31-3.
35. Wheatheral M, Maling TJ. Role of iron therapy for anaemia after orthopaedic surgery: randomized clinical trial. ANZ J Surg 2004; 74: 1049-51. (Pubitemid 40006987)
36. Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg Br 2005; 87-B: 213-7. (Pubitemid 40278023)
37. Prasad N, Rajamani V, Hullin D, Murray JM. Postoperative anaemia in femoral neck fracture patients: does it need treatment? A single blinded prospective randomised controlled trial. Injury 2009; 40: 1073-6.
38. Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am 2010; 92-A: 265-9.
39. Muñoz M, Breymann C, García-Erce JA, et al. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang 2008; 94: 172-83. (Pubitemid 351379653)
40. Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004; 15: S99-S106. (Pubitemid 39578823)
41. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004; 76: 74-8. (Pubitemid 38579543)
42. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13: 381-4.
43. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15: S93-S98. (Pubitemid 39578822)
44. Van Wyck DB. Labile iron: manifestations and clinical implications. J Am Soc Nephrol 2004; 15 (Suppl 2): S107-S111. (Pubitemid 39578824)
45. Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78: 480-91.
46. Goodnough LT, Merkel K. Parenteral iron and recombinant human erythropoietin therapy to stimulate erythropoiesis in patients undergoing repair of hip fracture. Hematology 1996; 1: 163-6. (Pubitemid 27037543)
47. Schmidt AH, Templeman DC, Kyle RF. Blood conservation in hip trauma. Clin Orthop 1998; 357: 68-73. (Pubitemid 29022434)
48. Cuenca J, García-Erce JA, Martínez AA, et al. Utilidad del hierro intravenoso en el tratamiento de la fractura de cadera en el anciano. Med Clin (Barc) 2004; 123: 281-5.
49. Cuenca J, García-Erce JA, Muñoz M, et al. Patients with pertrochanteric hip fracture may benefit from pre-operative intravenous iron therapy: a pilot study. Transfusion 2004; 44: 1447-52.
50. Cuenca J, García-Erce JA, Martínez AA, et al. Role of parenteral iron in the management of anaemia in the elderly patient undergoing displaced subcapital hip fracture repair: preliminary data. Arch Orthop Trauma Surg 2005; 125: 342-7. (Pubitemid 40895356)
51. Serrano-Trenas JA, Font-Ugalde P, Muñoz-Cabello L, et al. Role of perioperative intravenous iron therapy in elderly hip fracture patients: a single-center randomized controlled trial. Transfusion 2011; 51: 97-104.
52. García-Erce JA, Cuenca J, Muñoz M, et al. Peri-operative stimulation of erythropoiesis with intravenous iron and erythropoietin reduces transfusion requirements in patients with hip fracture. A prospective observational study. Vox Sang 2005; 88: 235-43. (Pubitemid 40704896)
53. García-Erce JA, Cuenca J, Haman-Alcober S, et al. Efficacy of preoperative recombinant human erythropoietin administration for reducing transfusion requirements in patients undergoing surgery for hip fracture repair. An observational cohort study. Vox Sang 2009; 97: 260-7.
54. Carson JL, Terrin ML, Barton FB, et al. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion 1998; 38: 522-9. (Pubitemid 28317227)
55. Grover M, Talwalkar S, Casbard A, et al. Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang 2006; 90:105-12. (Pubitemid 43381498)
56. Carson JL. Transfusion triggers in orthopedic patients. Transfus Altern Transfus Med 2011; 12: 9.
57. Foss NB, Kristensen MT, Jensen PS, et al. The effects of liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion 2009; 49: 227-34.
58. Muñoz M, García-Erce JA, Diéz-Lobo AI, et al. Utilidad de la administración de hierro sacarosa intravenoso para la corrección de la anemia preoperatoria en pacientes programados para cirugía mayor. Med Clin (Barc) 2009; 132: 303-6.
59. Theusinger OM, Leyvraz PF, Schanz U, et al. Treatment of iron deficiency anemia in orthopedic surgery with intravenous iron: efficacy and limits: A prospective study. Anesthesiology 2007; 107: 923-7. (Pubitemid 350175674)
60. Cuenca J, García-Erce JA, Martínez F, et al. Perioperative intravenous iron, with or without erythropoietin, plus restrictive transfusion protocol reduce the need for allogeneic blood after knee replacement surgery. Transfusion 2006; 46: 1112-9. (Pubitemid 44139484)
61. García-Erce JA, Cuenca J, Martínez F, et al. Perioperative intravenous iron preserves iron stores and may hasten the recovery from postoperative anaemia after knee replacement surgery. Transf Med 2006; 16; 335-41.
62. Karkouti K, McCluskey SA, Ghannam M, et al. Intravenous iron and recombinant erythropoietin for the treatment of postoperative anaemia. Can J Anesth 2006; 53: 11-19. (Pubitemid 43230987)
63. Bernière J, Dehullu JP, Gall O, Murat I. Intravenous iron in the treatment of postoperative anaemia in surgery of the spine in infants and adolescents. Rev Chir Orthop 1998; 84: 319-22.
64. Muñoz M, Naveira E, Seara J, et al. Role of parenteral iron on transfusion requirements after total hip replacement. A pilot study. Transfus Med 2006; 16: 137-42. (Pubitemid 43935070)
65. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. Ann Intern Med 2000; 133: 845-54.
66. Muñoz M, Naveira E, Seara J, et al. Postoperative iron after lower limb arthroplasty: a comparative study of the effects of 300 vs. 600 mg v iron administration on transfusion requirements. Transfus Altern Transfus Med 2011; 12: 34-5
67. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: Hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485-91.
68. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182-92. (Pubitemid 351677967)
69. García-Erce JA, Soria B, Cuenca J, et al. [Benefits from ambulatory administration of intravenous iron up to one gram per session]. LI Annual Meeting of the Spanish Association of Haematology and Haemotherapy, Barcelona 2009.
70. Kulnigg S, Teischinger L, Dejaco C, et al. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009; 104: 1460-7.
71. Evstatiev, R. Marteau P, Iqbal T, et al. Efficacy and safety of standardised ferric carboxymaltose doses vs. individually calculated iron sucrose doses for IBD-associated iron deficiency anemia: a multicentre, randomised controlled trial. Presented at the 18th United European Gastroenterology Week, Barcelona, 2010: P0420.
72. Weiss G, Meusburger E, Radacher G, et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64: 572-8. (Pubitemid 36871928)
73. Chertow GM, Mason PD, Vaaga-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378-82 (Pubitemid 43159991)
74. Stainsby D, Jones H, Asher D, et al SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006; 20: 273-82. (Pubitemid 44428107)
75. Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol 2008; 19: 833-4.
76. Coyne DW, Auerbach M. Anemia management in chronic kidney disease: intravenous iron steps forward. Am J Hematol 2010; 85: 311-2.
77. Weiss G. Iron and immunity: a double-edged sword. Eur J Clin Invest 2002; 32 (Suppl 1): 70-8. (Pubitemid 41704991)
78. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 1999; 55 (Suppl): S71-S78. (Pubitemid 29113587)
79. García-Erce JA, Cuenca J, Gómez-Ramírez S, et al. Posibilidades de tratamiento de la anemia perioperatoria en cirugía ortopédica y traumatología. Anemia 2009; 2: 17-27.
80. Huang X. Iron overload and its association with cancer risk in humans: evidence for iron as a carcinogenic metal. Mutat Res 2003; 533: 153-71. (Pubitemid 37487866)